Literature DB >> 9342205

Methylenetetrahydrofolate reductase variant and schizophrenia/depression.

T Arinami1, N Yamada, K Yamakawa-Kobayashi, H Hamaguchi, M Toru.   

Abstract

Patients with methylenetetrahydrofolate reductase (MTHFR) deficiency often show psychiatric manifestations. Since a common variant of the MTHFR gene, T677(Ala), responsible for the thermolabile MTHFR with less than 50% specific MTHFR activity, has been reported, we examined whether the T677 allele is associated with psychiatric disorders in an unrelated Japanese population consisting of 297 schizophrenics, 32 patients with major depression, 40 patients with bipolar disorder, and 419 controls. The genotype homozygous for the T677 allele was significantly frequently observed in schizophrenics with an odds ratio of 1.9 (P = 0.0006), and in patients with major depression with an odds ratio of 2.8 (P = 0.005). Our data suggest associations of the MTHFR gene variant with schizophrenia and depression in the Japanese.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9342205     DOI: 10.1002/(sici)1096-8628(19970919)74:5<526::aid-ajmg14>3.0.co;2-e

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  26 in total

1.  Psychotic symptoms in severe MTHFR deficiency and their successful treatment with betaine.

Authors:  Halvard Bönig; Gerhard Däublin; Bernd Schwahn; Udo Wendel
Journal:  Eur J Pediatr       Date:  2003-01-18       Impact factor: 3.183

Review 2.  Nutrition and depression: implications for improving mental health among childbearing-aged women.

Authors:  Lisa M Bodnar; Katherine L Wisner
Journal:  Biol Psychiatry       Date:  2005-07-25       Impact factor: 13.382

Review 3.  Avoiding mouse traps in schizophrenia genetics: lessons and promises from current and emerging mouse models.

Authors:  M Kvajo; H McKellar; J A Gogos
Journal:  Neuroscience       Date:  2011-07-27       Impact factor: 3.590

4.  Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment.

Authors:  David Mischoulon; Stefania Lamon-Fava; Jacob Selhub; Judith Katz; George I Papakostas; Dan V Iosifescu; Albert S Yeung; Christina M Dording; Amy H Farabaugh; Alisabet J Clain; Lee Baer; Jonathan E Alpert; Andrew A Nierenberg; Maurizio Fava
Journal:  CNS Spectr       Date:  2012-06       Impact factor: 3.790

5.  Methylenetetrahydrofolate reductase (MTHFR) polymorphism susceptibility to schizophrenia and bipolar disorder: an updated meta-analysis.

Authors:  Cai-Yun Hu; Zhen-Zhong Qian; Feng-Feng Gong; Shan-Shan Lu; Fang Feng; Yi-Le Wu; Hui-Yun Yang; Ye-Huan Sun
Journal:  J Neural Transm (Vienna)       Date:  2014-06-18       Impact factor: 3.575

6.  Association of MTHFR C677T polymorphism with schizophrenia and its effect on episodic memory and gray matter density in patients.

Authors:  Yanling Zhang; Hao Yan; Lin Tian; Fang Wang; Tianlan Lu; Lifang Wang; Jun Yan; Qi Liu; Lan Kang; Yanyan Ruan; Dai Zhang; Weihua Yue
Journal:  Behav Brain Res       Date:  2013-01-12       Impact factor: 3.332

Review 7.  The neuropsychiatry of inborn errors of metabolism.

Authors:  Mark Walterfang; Olivier Bonnot; Ramon Mocellin; Dennis Velakoulis
Journal:  J Inherit Metab Dis       Date:  2013-05-23       Impact factor: 4.982

8.  Folate metabolism genes, dietary folate and response to antidepressant medications in late-life depression.

Authors:  Brenda D Jamerson; Martha E Payne; Melanie E Garrett; Allison E Ashley-Koch; Marcy C Speer; David C Steffens
Journal:  Int J Geriatr Psychiatry       Date:  2012-12-20       Impact factor: 3.485

Review 9.  S-adenosyl-methionine in depression: a comprehensive review of the literature.

Authors:  George I Papakostas; Jonathan E Alpert; Maurizio Fava
Journal:  Curr Psychiatry Rep       Date:  2003-12       Impact factor: 5.285

10.  Meta-analysis of genetic association studies on bipolar disorder.

Authors:  Fayaz Seifuddin; Pamela Belmonte Mahon; Jennifer Judy; Mehdi Pirooznia; Dubravka Jancic; Jacob Taylor; Fernando S Goes; James B Potash; Peter P Zandi
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2012-05-09       Impact factor: 3.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.